Abiraterone (Zytiga®)
All Wales Medicines Strategy Group (AWMSG)
Record ID 32012000345
English
Authors' recommendations:
Abiraterone (Zytiga®) with prednisone or prednisolone is recommended for the treatment of metastatic castration resistant prostate cancer in adult men whose disease has progressed on or after a docetaxel-based chemotherapy regimen.
This recommendation applies only in circumstances where the approved Wales Patient Scheme for access to medicines is utilised.
AWMSG is of the opinion that abiraterone (Zytiga®) is suitable for specialist only prescribing within NHS Wales for the above indication.
Details
Project Status:
Completed
Year Published:
2012
URL for published report:
http://www.wales.nhs.uk/sites3/docmetadata.cfm?orgid=371&id=186534&pid=24773
English language abstract:
An English language summary is available
Publication Type:
Not Assigned
Country:
Wales, United Kingdom
MeSH Terms
- Prostatic Neoplasms
- Abiraterone Acetate
- Antineoplastic Agents
- Prostatic Neoplasms, Castration-Resistant
- Androgen Antagonists
Contact
Organisation Name:
All Wales Medicines Strategy Group
Contact Address:
All Wales Therapeutics and Toxicology Centre, Academic Centre, University Hospital Llandough, Penlan Road, Penarth, Vale of Glamorgan CF64 2XX
Contact Name:
AWTTC@wales.nhs.uk
Contact Email:
AWTTC@wales.nhs.uk
Copyright:
AWTTC
This is a bibliographic record of a published health technology assessment from a member of INAHTA or other HTA producer. No evaluation of the quality of this assessment has been made for the HTA database.